First UPlink infectious disease test is for C difficile
This article was originally published in Clinica
Executive Summary
The first infectious disease product to be developed by OraSure Technologies and its partner Meridian Bioscience using the phosphor-based UPlink technology will be a test for Clostridium difficile toxins A and B, which will be used in the diagnosis of C difficile-associated disease. OraSure has already filed for 510(k) approval for UPlink-based assays for cocaine, opiate and amphetamines (see Clinica No 947, p 18).